Health

STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/10/2026, 17:51:25 UTC.

Briefings

Lilly's investigational retatrutide demonstrated superior efficacy in a head-to-head study against Novo Nordisk's Ozempic for diabetes management. Participants on the highest dose of retatrutide achieved a 2.2 percentage-point reduction in A1c over 80 weeks compared to 1.8% for Ozempic, while losing 20.9% versus 9.4% of body weight. The findings highlight retatrutide's potential as a more effective weight and glucose-lowering agent, though the study excluded non-treatment participants.

Key points

• Lilly's retatrutide showed a 2.2 percentage-point reduction in A1c over 80 weeks versus 1.8% for Ozempic in a head-to-head study.
• Retatrutide participants lost 20.9% of body weight compared to 9.4% for Ozempic at the highest dose.

Context

This study compares Lilly's investigational retatrutide against Novo Nordisk's Ozempic for diabetes management, with results indicating retatrutide's superior efficacy in lowering blood sugar and reducing weight.

Limitations

Results are based only on participants who stayed on treatment; non-treatment participants were excluded from the analysis.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 07:30:57 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiegq57wejmoa6ttih6vokxl7fpf3knlqbxxykxxdbepdz6uzjlvs4